Developing a low-cost and accessible COVID-19 vaccine for global health

PLoS Negl Trop Dis. 2020 Jul 29;14(7):e0008548. doi: 10.1371/journal.pntd.0008548. eCollection 2020 Jul.

Authors

Peter J Hotez^{1

2

3

4}, Maria Elena Bottazzi^{1

2}

Affiliations

¹ Texas Children's Center for Vaccine Development, Departments of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
² Department of Biology, Baylor University, Waco, Texas, United States of America.
³ Hagler Institute for Advanced Study at Texas A&M University, and Scowcroft Institute of International Affairs, Bush School of Government and Public Service, Texas A&M University, College Station, Texas, United States of America.
⁴ James A. Baker III Institute of Public Policy, Rice University, Houston, Texas, United States of America.

No abstract available

MeSH terms

Animals
Antibodies, Neutralizing / immunology
Antibodies, Viral / immunology
Betacoronavirus / immunology*
COVID-19
COVID-19 Vaccines
Coronavirus Infections / economics
Coronavirus Infections / immunology
Coronavirus Infections / prevention & control*
Cross Protection
Developing Countries
Global Health*
Humans
Neutralization Tests
Pandemics / prevention & control*
Pneumonia, Viral / prevention & control*
Protein Interaction Domains and Motifs
SARS-CoV-2
Severe Acute Respiratory Syndrome / prevention & control
Severe acute respiratory syndrome-related coronavirus / immunology
Spike Glycoprotein, Coronavirus / chemistry
Spike Glycoprotein, Coronavirus / immunology
Technology Transfer
Vaccines, Subunit / adverse effects
Vaccines, Subunit / economics
Vaccines, Subunit / immunology
Vaccines, Subunit / supply & distribution
Vaccines, Synthetic / adverse effects
Vaccines, Synthetic / economics
Vaccines, Synthetic / immunology
Viral Vaccines* / adverse effects
Viral Vaccines* / economics
Viral Vaccines* / immunology
Viral Vaccines* / supply & distribution

Substances

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
Spike Glycoprotein, Coronavirus
Vaccines, Subunit
Vaccines, Synthetic
Viral Vaccines
spike glycoprotein, SARS-CoV
spike protein, SARS-CoV-2

Grants and funding

The authors received no specific funding for this work.